《IHE：2025年欧洲癌症比较报告：疾病负担、成本及药物与分子诊断可及性（英文版）（234页）.pdf》由会员分享，可在线阅读，更多相关《IHE：2025年欧洲癌症比较报告：疾病负担、成本及药物与分子诊断可及性（英文版）（234页）.pdf（234页珍藏版）》请在三个皮匠报告上搜索。

1、 ihe.se Comparator Report on Cancer in Europe 2025-Disease Burden,Costs and Access to Medicines and Molecular Diagnostics Andrea Manzano,Christer Svedman,Thomas Hofmarcher,Nils Wilking COMPARATOR REPORT ON CANCER IN EUROPE 2025 IHE REPORT 2025:2 2 Authors:Andrea Manzano,IHE-The Swedish Institute for

2、 Health Economics,Stockholm,Sweden Christer Svedman,N-Power Medicine Inc,Redwood City,CA,USA Thomas Hofmarcher,IHE-The Swedish Institute for Health Economics,Lund,Sweden Nils Wilking,Department of Oncology-Pathology,Karolinska Institutet,Stockholm,Sweden Please cite this report as:Manzano A,Svedman

3、C,Hofmarcher T,Wilking N.Comparator Report on Cancer in Europe 2025-Disease Burden,Costs and Access to Medicines and Molecular Diagnostics.IHE REPORT 2025:2.IHE:Lund,Sweden.Disclosure:This report was commissioned and funded by EFPIA-the European Federation of Pharmaceutical Industries and Associatio

4、ns.EFPIA and members of the EFPIA Oncology Platform had no editorial control over the content of this report.The views and opinions of the authors are not necessarily those of EFPIA or any of its members.The responsibility for the analysis and conclusions in this report lies solely with the authors.

5、IHE REPORT 2025:2 e-ISSN:1651-8187 ISSN:1651-7628 IHE-The Swedish Institute for Health Economics,Lund,Sweden The report can be downloaded from IHEs website(www.ihe.se).COMPARATOR REPORT ON CANCER IN EUROPE 2025 IHE REPORT 2025:2 3 Foreword-20 years of Comparator Reports We published the first Compar

6、ator Report in 2005 against the backdrop of the approval of the very first targeted cancer medicines such as rituximab,trastuzumab,and imatinib at the turn of the millennium.Combining our expertise in health economics and medical oncology,the report examined the disease and economic burden of cancer